Hindorf C, Flux G D, Ibisch C, Kraeber Bodéré F
Imagerie Médicale, Oniris, Nantes, France.
Q J Nucl Med Mol Imaging. 2011 Apr;55(2):198-204.
Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency ((153)Sm-EDTMP and (89)Sr-Cl₂) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries ((186)Re-HEDP, (117)Snm-DTPA and (223)Ra-Cl₂). The tissues at risk for the treatment are bone marrow and normal bone. A review of the methods applied for dosimetry for these tissues and for tumours is performed, including the calculation of S values (the absorbed dose per decay) and optimal procedures on how to obtain biodistribution data for each radiopharmaceutical. The dosimetry data can be used to individualise and further improve the treatment for each patient. Dosimetry for radionuclide therapy of bone metastases is feasible and can be performed in a routine clinical practice.
放射性核素治疗成功地用于多部位硬化性骨转移瘤的治疗。缓解疼痛是最常见的治疗目的。目前欧洲药品管理局批准了两种放射性药物（（153）Sm-EDTMP和（89）Sr-Cl₂），而其他放射性药物正处于不同的研发阶段，或在一些欧洲国家已获批准（（186）Re-HEDP、（117）Snm-DTPA和（223）Ra-Cl₂）。治疗中面临风险的组织是骨髓和正常骨。对用于这些组织和肿瘤剂量测定的方法进行了综述，包括S值（每次衰变的吸收剂量）的计算以及获取每种放射性药物生物分布数据的最佳程序。剂量测定数据可用于为每位患者进行个体化治疗并进一步改善治疗效果。骨转移瘤放射性核素治疗的剂量测定是可行的，并且可以在常规临床实践中进行。
